Alumis Inc. raised $259M in a Series C financing led by Foresite Capital, Samsara BioCapital and venBio Partners to advance its clinical-stage pipeline of oral therapies designed to address immune dysfunction.
Amount Raised
$259 Million
Round Type
Series C
Los AngelesBiotechnologyHealthcareHealth CareInvestors
Description
Alumis Inc. announced an upsized $259M Series C financing to advance its clinical-stage pipeline of oral therapies designed to address immune dysfunction. The financing was co-led by existing investor, Foresite Capital, and new investors, Samsara BioCapital and venBio Partners, with additional participation from other investors like Cormorant Asset Management, SR One, Lilly Asia Ventures, and more.
Quick answer
Alumis raised $259 Million in a Series C round, dated March 7, 2024. Investors: Cormorant Asset Management, Lilly Asia Ventures, Ayur Maya, Ally Bridge Group, Nextech, Samsara Bio Capital, Ven Bio Partners and SR One. Alumis is based in Los Angeles, California, United States.
- How much did Alumis raise?
- Alumis raised $259 Million in a Series C round on March 7, 2024.
- Who invested in Alumis?
- Cormorant Asset Management, Lilly Asia Ventures, Ayur Maya, Ally Bridge Group, Nextech, Samsara Bio Capital, Ven Bio Partners and SR One are named as investors in this round.
- What does Alumis do?
- A California-based biotech company specializing in developing oral therapies for immune dysfunction and autoimmune indications, with a focus on TYK2 inhibition.
- Where is Alumis based and how big is it?
- Alumis is based in Los Angeles, California, United States.
- Who are the decision-makers at Alumis?
- Fundz holds 1 contact at Alumis. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Biotechnology around the same time
Companies in the same sectors as Alumis that raised within 45 days of this round, from Fundz verified event records.
- BioLineRx Ltd raised $20M (Pre-Seed) on April 10, 2024.
- Enlaza Therapeutics raised $84M on April 5, 2024.
- Vaccinex raised $1.8M (Seed) on March 29, 2024.
- Vaccinex raised $1.2M (Seed) on March 28, 2024.
- ViaLase raised $38M on March 25, 2024.
- Novabay raised $665K (Seed) on March 24, 2024.
Who to call at Alumis, and when
A new round usually means Alumis is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Alumis raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alumis, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alumis. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alumis raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Alumis raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.